Epigral 将来の成長
Future 基準チェック /36
Epigral利益と収益がそれぞれ年間16.1%と20.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.4% 16.1%なると予測されています。
主要情報
16.1%
収益成長率
16.12%
EPS成長率
| Chemicals 収益成長 | 19.4% |
| 収益成長率 | 20.2% |
| 将来の株主資本利益率 | 16.40% |
| アナリストカバレッジ | Low |
| 最終更新日 | 03 May 2026 |
今後の成長に関する最新情報
分析記事 • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...分析記事 • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Recent updates
ナラティブの更新 • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).分析記事 • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...ナラティブの更新 • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).ナラティブの更新 • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.ナラティブの更新 • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.ナラティブの更新 • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.ナラティブの更新 • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.ナラティブの更新 • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).ナラティブの更新 • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.ナラティブの更新 • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).分析記事 • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...分析記事 • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...分析記事 • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...分析記事 • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブの更新 • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.分析記事 • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...分析記事 • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...分析記事 • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...分析記事 • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...分析記事 • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
新しいナラティブ • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.分析記事 • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...分析記事 • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...分析記事 • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...分析記事 • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...分析記事 • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...分析記事 • Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2028 | 38,429 | 4,606 | 1,497 | 6,497 | 1 |
| 3/31/2027 | 33,920 | 4,046 | -887 | 5,113 | 1 |
| 3/31/2026 | 25,272 | 3,320 | 414 | 4,355 | N/A |
| 12/31/2025 | 24,187 | 3,379 | N/A | N/A | N/A |
| 9/30/2025 | 24,668 | 4,024 | 1,425 | 4,894 | N/A |
| 6/30/2025 | 25,055 | 4,325 | N/A | N/A | N/A |
| 3/31/2025 | 25,501 | 3,577 | 2,459 | 4,406 | N/A |
| 12/31/2024 | 24,471 | 3,481 | N/A | N/A | N/A |
| 9/30/2024 | 22,734 | 2,935 | 1,751 | 4,323 | N/A |
| 6/30/2024 | 21,255 | 2,502 | N/A | N/A | N/A |
| 3/31/2024 | 19,292 | 1,959 | -8 | 3,976 | N/A |
| 12/31/2023 | 19,667 | 1,953 | N/A | N/A | N/A |
| 9/30/2023 | 20,331 | 2,234 | 679 | 5,174 | N/A |
| 6/30/2023 | 21,104 | 2,770 | N/A | N/A | N/A |
| 3/31/2023 | 21,884 | 3,533 | 2,097 | 6,262 | N/A |
| 12/31/2022 | 21,250 | 3,756 | N/A | N/A | N/A |
| 9/30/2022 | 20,093 | 3,682 | 155 | 4,202 | N/A |
| 6/30/2022 | 17,934 | 3,236 | N/A | N/A | N/A |
| 3/31/2022 | 15,509 | 2,528 | -1,725 | 2,838 | N/A |
| 3/31/2021 | 8,286 | 1,008 | 324 | 2,292 | N/A |
| 3/31/2020 | 6,098 | 1,141 | -2,046 | 1,646 | N/A |
| 3/31/2019 | 7,104 | 1,828 | N/A | 2,613 | N/A |
| 3/31/2018 | 5,975 | 1,555 | N/A | 2,249 | N/A |
| 3/31/2017 | 3,921 | 665 | N/A | 1,385 | N/A |
| 3/31/2016 | 3,982 | 672 | N/A | 1,234 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: EPIGRALの予測収益成長率 (年間16.1% ) は 貯蓄率 ( 6.9% ) を上回っています。
収益対市場: EPIGRALの収益 ( 16.1% ) Indian市場 ( 16.2% ) よりも低い成長が予測されています。
高成長収益: EPIGRALの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: EPIGRALの収益 ( 20.2% ) Indian市場 ( 10.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: EPIGRALの収益 ( 20.2% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: EPIGRALの 自己資本利益率 は、3年後には低くなると予測されています ( 16.4 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 23:04 |
| 終値 | 2026/05/25 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Epigral Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |